Building a Tox-and-Filler Loyalty Stack: Layering Allē, Aspire, and Evolus Rewards Without Cannibalizing Margin

What the stack actually is

Each major manufacturer runs a consumer loyalty program tied to its portfolio:

• Allē sits over the AbbVie / Allergan Aesthetics line — Botox, the Juvéderm family, and more.
• Aspire covers Galderma's portfolio — Dysport, the Restylane family, Sculptra.
• Evolus Rewards is tied to Jeuveau.

Patients accrue points and offers on qualifying treatments, and many of them track that standing closely. For the patient, it's savings and status. For you, it's a built-in reason for them to come back and to treat — provided you're stocking the products their points favor.

The benefit: acquisition and retention you didn't pay for

The upside is real and worth leaning into. A patient enrolled in a program has a financial and psychological reason to return to a practice that honors it, to treat on a regular cadence, and to choose treatments within that portfolio. Surfacing program value at the front desk — making sure patients are enrolled, that they understand their standing, and that booking captures it — is a conversion and retention lever that costs you nothing but attention. Practices that ignore enrollment are leaving free retention on the table.

The trap: letting the stack choose your inventory

Here's where it turns. Because patients chase points, demand can quietly bend your stocking toward whatever the programs reward rather than whatever your clinical plan and your margin favor. Layer all three programs without a strategy and you fragment your purchasing across three portfolios — which can drop your practice-level rebate tiers and weaken your loyalty standing on the products you actually use most. The patient-facing points look like savings; the back-end fragmentation looks like a higher loaded cost on everything.

The deeper risk is behavioral: a patient trained to treat based on points balance rather than on the plan their injector recommended is a patient making clinical decisions for financial-program reasons. That's bad medicine dressed as a good deal, and it's not a habit you want your practice to cultivate.

Anchoring without losing reach

The practices that run the stack instead of being run by it usually anchor primarily to one portfolio — concentrating volume to hold the strongest tier and rebate position — while selectively offering products from another ecosystem to serve genuine demand they'd otherwise lose. They surface loyalty value to patients enthusiastically, but they keep the treatment plan upstream of the points: the injector recommends based on the patient's face, and the program is applied to whatever that plan calls for, not the other way around.

What to do

• Pick a primary ecosystem and concentrate volume there to protect your tier and rebate standing, rather than spreading thin across all three.
• Maximize enrollment and point capture at the front desk — it's free retention you're probably under-using.
• Keep the clinical plan upstream of the points. The injector recommends; the loyalty program is applied to the recommendation, never the driver of it.
• Audit whether the stack is steering your inventory. If you're stocking products primarily because patients' points favor them and not because your plan or margin does, the programs are running you.

The loyalty stack is one of the few places in this business where a third party does your customer acquisition for free. The discipline is accepting the gift without letting the giver redesign your inventory, fragment your buying power, or teach your patients that the right treatment is whichever one earns the most points.